Indefinite Delivery Contract HHSD200201459750I

Pfizer Inc. holds a Federal Supply Schedule (FSS-61-IB) contract with the U.S. General Services Administration to provide pharmaceuticals and drugs to federal agencies. This $6.25 billion multiple-award contract enables Pfizer to deliver a wide range of pharmaceutical products, including controlled substances, antibiotics, vaccines, and other medications, to support the healthcare needs of federal customers such as the Department of Defense, Department of Veterans Affairs, and Centers for...

Pfizer Inc. holds a multiple-award Federal Supply Schedule contract valued at $7.31 billion for the procurement of drugs, pharmaceuticals, and hematology-related products under General Services Administration (GSA) schedule 65 I B. The contract was awarded on July 1, 2024, with an ultimate completion date of June 30, 2029, and is funded by the Veterans Integrated Service Network 12, a component of the Department of Veterans Affairs. As a large, established pharmaceutical manufacturer, Pfizer...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Pfizer Inc., a global pharmaceutical manufacturer, to provide the drug Oxybryta. The single-award BPA has a ceiling value of $1,300,000.00 and a period of performance through August 29, 2024. Pfizer, as a prime contractor, will supply the pharmaceutical product Oxybryta to support the agency's healthcare initiatives. Pfizer holds several significant Indefinite Delivery Vehicles with...

Pfizer Inc. was awarded a single-award Indefinite Delivery Contract valued at $74.0 million by the National Acquisition Center on September 15, 2025, for the supply of Rituximab and FDA-licensed biosimilar products to multiple federal healthcare agencies including the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract operates under a base ordering period from September 15, 2025, through September 14,...

Pfizer Inc. has been awarded a multiple-award Indefinite Delivery Contract by the Centers for Disease Control and Prevention (CDC) for the procurement of COVID-19 adult vaccines. This contract, valued at $347.2 million, was executed on June 1, 2024, with an ultimate completion date of September 30, 2025. The contract does not utilize small business set-aside designations, reflecting Pfizer's status as an established pharmaceutical manufacturer capable of meeting extensive government medical...

Pfizer Inc. has been awarded a multiple-award Indefinite Delivery Contract by the Centers for Disease Control and Prevention (CDC) Pittsburgh for the supply of adult vaccines, with a contract ceiling value of $117.8 million and a performance period extending from July 1, 2025 through June 30, 2026. This civilian contract carries no small business set-aside designation, reflecting Pfizer's established capacity as a large pharmaceutical manufacturer. The contract structure enables the CDC to issue...

This indefinite delivery contract (IDC) was awarded by the National Acquisition Center, a civilian agency, to Pfizer Inc. as the prime contractor. The contract has a ceiling value of $66,935,445.85 and a period of performance from October 8, 2020 to October 7, 2025, with four one-year option periods. The purpose of this IDC is to provide the U.S. federal government with a source for Epoetin vials, a critical pharmaceutical product. As one of the world's largest pharmaceutical companies, Pfizer...

This Indefinite Delivery Contract was awarded by the Defense Logistics Agency Troop Support Medical, a component of the Department of Defense, to the prime contractor Pfizer Inc., a large pharmaceutical manufacturer. The contract has a ceiling value of $48,683,160.88 and a period of performance through August 31, 2030. It does not utilize any small business set-asides. The contract primarily aims to procure a wide range of pharmaceutical products and medical supplies for the Department of...

The provided information describes an Indefinite Delivery Contract (IDC) awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a leading global pharmaceutical corporation. The $425.5 million IDC, with a period of performance running from June 2023 to June 2024, is for the procurement of adult COVID-19 vaccines. As a major supplier of pharmaceutical products and vaccines to the U.S. federal government, Pfizer holds several significant Indefinite Delivery Vehicles (IDVs),...

This Indefinite Delivery Contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian federal agency, to Pfenex Inc. The contract covers the advanced development of RPA563 and PX563L, with a single award and a total ceiling value of $144,092,373.11. The contract has an ultimate completion date of March 30, 2020, with an award date of August 14, 2015. No set-asides were used for this contract. The purpose of this contract is to support the...